louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01888549: Efficacy of Proton Pump Inhibitor for Chronic Cough Caused by Gastroesophageal Reflux; Double-blind, Placebo-controlled, Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Cough Caused by Gastroesophageal Reflux
Keywords: Chronic cough, proton pump inhibitor, GERD, nonacid reflux,
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2013-06-27
Enrollment: 48
Sex: ALL
Minimum age (years): 19
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Efficacy of proton pump inhibitor for chronic cough caused by gastroesophageal reflux; double-blind, placebo-controlled, randomized clinical trial


Eligibility criteria: Inclusion Criteria:

ages of 18 and 70 years had chronic cough of \>8 weeks in duration

Exclusion Criteria:

1. abnormal chest X ray, PNS view 2. previous surgical or endoscopic antireﬂux procedure 3. previous aerodigestive malignancy or Barrett's oesophagus 4. current smokers or ex-smok-ers (deﬁned as those who quit smoking \<3 months prior to study enrolment or those who have quit, but have a 20 pack year smoking history) 5. Malignancy History (lung cancer, esophageal cancer etc.) 6. upper respiratory infection within 8 weeks of study enrolment 7. currently using a PPI, H2 blocker, beta-blocker, angiotensin-converting enzyme inhibitor, corticosteroid, methylxanthine, inhaled beta-agonist, anti-inﬂammatory agent or anticholinesterase drug at time of enrolment

Primary outcomes:
measure: change in LCQ score and cough VAS, comparing PPI-treated group to placebo
timeFrame: change in LCQ score after 4 weeks and 8 weeks
Secondary outcomes:
measure: change in LCQ score and cough VAS, comparing PPI-treated group to placebo
timeFrame: change in cough VAS after 4weeks and 8 weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Gangnam severance hospita
Study officials:
References:
citation: Park HJ, Park YM, Kim JH, Lee HS, Kim HJ, Ahn CM, Byun MK. Effectiveness of proton pump inhibitor in unexplained chronic cough. PLoS One. 2017 Oct 10;12(10):e0185397. doi: 10.1371/journal.pone.0185397. eCollection 2017.
Clinical trial NCT06859749: Does educatıonal Escape Game Affect Students' motıvatıon, academıc Self-effıcacy and Success Levels: a quası-experımental Study
Official title: Does educatıonal Escape Game Affect Students' motıvatıon, academıc Self-effıcacy and Success Levels
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Motivation
Self Efficacy
Lead sponsor: Muş Alparslan University
Sponsor class: OTHER
First posted: 2025-03-05
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This is a semi-experimental study. The study aimed to examine the effects of an educational escape game on students' motivation, academic self-efficacy and achievement levels. Students studying in an elderly care program will be included in the study. Students will be divided into 2 groups according to their branches: experimental (educational escape game) and control (question-answer).

H1. Students participating in the escape game will show significantly higher motivation in the "Motivation Scale for Teaching Materials" than students participating in the question-answer method.

H2. Students participating in the escape game will show significantly higher self-efficacy in the "Academic Self-Efficacy Scale" than students participating in the question-answer method.

H3. Students participating in the escape game will show significantly higher success in the "Achievement Test" than students participating in the question-answer method.


Eligibility criteria: Inclusion Criteria:

* Being over 18 years of age,
* Receiving education in an elderly care program,
* Not having previously taken the "Elderly Care Principles and Practices I" and "Elderly Care Principles and Practices II" courses,
* Providing attendance during data collection processes.
* Having a phone and internet that can enter Google forms.

Exclusion Criteria:

* Being under 18 years of age,
* Not cooperating,
* Having previously taken the "Elderly Care Principles and Practices I" and "Elderly Care Principles and Practices II" courses,
* Being absent.

Primary outcomes:
measure: Motivation average
timeFrame: 1 months
Secondary outcomes:
Other outcomes:
Locations:
city: Muş
country: Turkey
facility: Muş Alparslan University
Study officials:
References:
Clinical trial NCT04444349: Protective Effect of CoQ10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiovascular Surgery (PANDA V)
Official title: Protective Effect of Coenzyme Q10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiac and Aortic Surgery (PANDA V): a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cardiovascular Disease
Keywords: inflammatory response
Lead sponsor: Nanjing Medical University
Sponsor class: OTHER
Collaborators: name: The First Affiliated Hospital with Nanjing Medical University
name: Beijing Anzhen Hospital
name: West China Hospital
name: The First Affiliated Hospital of Guangzhou Medical University
First posted: 2020-06-23
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Cardiovascular diseases are the leading causes of death and prescription drug use. Research on certain dietary supplements looks promising as a way to help reduce risk factors. Previous studies showed that CoQ10 levels were decreased in cardiovascular patients and worsening of mitochondrial dysfunction was observed. The overall objective of this study is to determine if supplementing with CoQ10 can reduce inflammatory risk factors in adults with cardiac surgery, independent of other dietary or physical activity changes.


Eligibility criteria: Inclusion Criteria:

* Adult men and women
* Who receive cardiovascular surgery
* Agree to participate in the surgery and sign the informed consent form

Exclusion Criteria:

* Pregnant or planning on getting pregnant during the study
* Contain a minimum of 2 traits of metabolic syndrome
* Refused to participate in the surgery and refused informed consent

Primary outcomes:
measure: C-reactive protein
timeFrame: Change from baseline of CRP in mg/L at 5 days after surgery.
Secondary outcomes:
measure: Interleukin-6
timeFrame: Change from baseline of IL-6 in pg/mL at 5 days after surgery.
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Anzhen Hospital
state: Beijing
city: Guangzhou
country: China
facility: The First Affiliated Hospital of Guangzhou Medical University
state: Guangdong
city: Nanjing
country: China
facility: The First Affiliated Hospital of Nanjing Medical University
state: Jiangsu
city: Chengdu
country: China
facility: West China Hospital of Sichuan University
state: Sichuan
Study officials:
References:
Clinical trial NCT00206349: Ability to Cope With Type 1 Diabetes
Official title: Evaluation of Coping Skills in Type 1 Diabetes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Depression
Keywords: Depression
Socioeconomic status
Type 1 diabetes mellitus
Children
Adolescents
Lead sponsor: Baylor College of Medicine
Sponsor class: OTHER
First posted: 2005-09-21
Enrollment: 220
Sex: ALL
Minimum age (years): 8
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE

Brief summary: The purpose of this study is to learn about the relationship that exists between coping skills and blood glucose control. In addition to this, we will study the effect of Type 1 diabetes on coping skills in different age groups, genders, ethnicities, socioeconomic groups, and the duration of diabetes.

Detailed description: Coping with type 1 diabetes can be very difficult. Type 1 diabetes is a very unique chronic disease because it requires constant attention to several responsibilities such as daily glucose monitoring, multiple daily insulin doses, and strict diet and exercise. Several studies have shown that increased rates of poorer glucose control are a result of struggling to cope with type 1 diabetes. This may be due to the fact that many type 1 diabetics experience a feeling of exhaustion, or "burnout," after a certain period of time due to an overwhelming amount of responsibility.

In our study we would like to determine how children's ability to cope with diabetes affects glucose control. By completing several questionnaires, we can analyze different kinds of coping skills through a complex scoring system. These scores will then be analyzed in comparison to your glucose control using HbA1c.

Eligibility criteria: Inclusion Criteria:

* Subjects must be type 1 diabetic
* English/Spanish speaking
* The legal guardian must be present

Exclusion Criteria:

* Non-cognitive or mentally ill
* Under the age of 8.0 years

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: Texas Children's Hospital
state: Texas
Study officials:
affiliation: Baylor College of Medicine
name: Rubina A Heptulla, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06087549: PENG Block vs. ESP Block for Pediatric Hip Surgery
Official title: PENG Block vs. ESP Block for Pediatric Hip Surgery. A Randomized, Prospective Double-blinded Clinical Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hip Dysplasia
Hip Injuries
Hip Fractures
Hip Disease
Lead sponsor: Poznan University of Medical Sciences
Sponsor class: OTHER
First posted: 2023-10-17
Enrollment: 90
Sex: ALL
Minimum age (years): 2
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Three groups:

Group I -control Group II - PENG block Group III - ESP block
Primary purpose: TREATMENT

Brief summary: The study compares the effectiveness and safety of the pericapsular nerve blockade vs. ESPB in pediatric patients who underwent hip surgeries.

Detailed description: The study compares the effectiveness and safety of the pericapsular nerve blockade vs. ESPB in pediatric patients who underwent hip surgeries. In addition, we aim to determine the optimal volume of local anesthetics needed to achieve a satisfactory level of analgesia.

Eligibility criteria: Inclusion Criteria:

- pediatric patients aged between 0-12 years who will undergo hip surgery

Exclusion Criteria:

* a history of chronic pain use of gabapentin/pregabalin for \> 3 months opioid use \> 1 repeated opioid prescription in the last three months
* morbid obesity (BMI \> 99th percentile)
* Infection at block application area
* coagulopathy

Primary outcomes:
measure: FLACC score
timeFrame: 48 hours after surgery
Secondary outcomes:
measure: NLR
timeFrame: 48 hours after surgery
measure: PLR
timeFrame: 48 hours after surgery
measure: total opioid consumption
timeFrame: 48 hours after surgery
Other outcomes:
Locations:
city: Poznań
country: Poland
facility: Department of Spine Diseases and Pediatric Orthopedics, University of Medical Sciences, Poznań, Poland
state: Wielkopolska
Study officials:
affiliation: Poznań University of Medical Sciences
name: Tomasz Kotwicki, Prof.dr hab
role: STUDY_CHAIR
References:
Clinical trial NCT06942949: Evaluation of Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stones, A Pivotal Trial
Official title: Evaluation of Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stones, A Pivotal Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Kidney Calculi; Ureteral Calculi
Lead sponsor: Avvio Medical
Sponsor class: INDUSTRY
First posted: 2025-04-24
Enrollment: 101
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and performance of the ELS to treat urinary stones. The ELS is intended to break urinary stones into small fragments that can pass during or after the procedure with less or no discomfort. Eligible patients are male or females, age 21 or older, with a single urinary stone in the ureter. Participants will undergo the ELS procedure and then be evaluated 30 days later for the presence or absence of urinary stone fragments on a CT scan. Other outcome measures will be changes in pain, quality of life, and return to normal daily activities/work.


Eligibility criteria: Inclusion Criteria:

* Male or Female aged \>=21 Years
* Provides written informed consent
* One urinary stone within the ureter, size \>=5 mm and \<=10 mm
* Stone is indicated for Shock Wavve Lithotrips Per AUA 2016 guidelines
* Urinary stone is present on a CT scan within past 14 days

Exclusion Criteria:

* Anatomic presentations that would preclude obtaining an acoustic window for the ultrasound treatment
* Medical Expulsion Therapy (e.g., Flomax)
* Non-calcium based stones (e.g., uric acid stones)
* Untreated UTI
* Presence of abnormal skin conditions in the area to be treated
* Coagulation abnormality
* Inability to lay still for 30 minutes
* Pregnant
* Abnormal Kidney Function
* Any genitourinary history or procedure that has altered anatomy (e.g. urinary tract reconstruction)

Primary outcomes:
measure: Primary Outcome Measure
timeFrame: From ELS treatment to 30 Days afterward.
Secondary outcomes:
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Arizona State Urological Research Institute
state: Arizona
city: Sacramento
country: United States
facility: Golden State Urology
state: California
city: Lake Barrington
country: United States
facility: Comprehensive Urologic Care
state: Illinois
city: Wichita
country: United States
facility: Wichita Urology Group
state: Kansas
city: Las Vegas
country: United States
facility: Sheldon Freedman, MD
state: Nevada
city: San Antonio
country: United States
facility: Urology San Antonio
state: Texas
Study officials:
References:
Clinical trial NCT00614549: Efficacy and Safety of Levetiracetam in Routine Clinical Practice in Czech and Slovak Republics, Hungary, and Romania.
Official title: Long-term Evaluation of the Efficacy and Safety of Levetiracetam in Routine Clinical Practice in the Czech and Slovak Republics, Hungary, and Romania - Non-interventional Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Epilepsy
Keywords: Levetiracetam
Keppra
Epilepsy
Efficacy
Safety
Lead sponsor: UCB Pharma
Sponsor class: INDUSTRY
First posted: 2008-02-13
Enrollment: 2569
Sex: ALL
Minimum age (years): 4
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary care clinics and hospitals.

Brief summary: To evaluate, over 1 year period, the efficacy and safety of newly prescribed levetiracetam as add-on treatment (POS, myoclonoc seizures in JME and PGTCS in IGE) or primary monotherapy (partial onset seizures) in adult and paediatric patients within the approved age limits in routine clinical practice in Czech and Slovak Republics, Hungary, and Romania. Non-interventional study.


Eligibility criteria: Inclusion Criteria:

* diagnoses of partial onset seizures (POS) with or without secondary generalisation or Juvenile Myoclonic Epilepsy (JME) or another IGE with PGTCS
* newly prescribed levetiracetam as add-on treatment (POS, myoclonic seizures in JME and PGTCS in IGE) or monotherapy (partial onset seizures only) in newly diagnosed patients. Newly prescribed means inclusion of the patients in whom a decision has been made to prescribe LEV and the first dose is just to be prescribed.
* age 4 years or above for partial onset seizures, 12 years or above for MS in JME or PGTCS in IGE, 16 years or above for monotherapy
* patient written informed consent

Exclusion Criteria:

* indications other than those defined in inclusion criteria
* history of allergic or anaphylactic reactions to levetiracetam or other pyrrolidone derivatives and excipients included

Primary outcomes:
measure: Retention rate after 6 and 12 months
timeFrame: 6 and 12 months
Secondary outcomes:
measure: Seizure freedom for the last 6 and 12 months
timeFrame: 6 and 12 months
Other outcomes:
Locations:
Study officials:
affiliation: +1 877 822 9493 (UCB)
name: UCB Clinical Trial Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT04470349: Comparison of Dynamic Distraction Systems in Proximal Interphalangeal Joint Fractures
Official title: Comparison of Dynamic Distraction Systems in Proximal Interphalangeal Joint Fractures
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Proximal Interphalangeal Joint Fracture of the Hand
Lead sponsor: Waldfriede Hospital
Sponsor class: OTHER
First posted: 2020-07-14
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People who have sustained a proximal interphalangeal fracture treated with external dynamic fixator

Brief summary: Fractures of the proximal interphalangeal joints continue to pose significant management challenges. Thus the aim of our study is to compare two dynamic finger joint distractors (Litos® and Ligamentotaxor®) in respect to the radiological standard follow-up examination and functional assessments.


Eligibility criteria: Inclusion Criteria:

* proximal interphalangeal fracture treated with external dynamic fixator
* Operative care \<21 days from trauma
* Age between 18 and 90 years.
* Male and female

Exclusion Criteria:

- additional fractures or disabilities of the hand

Primary outcomes:
measure: Disabilities of Arm, Shoulder and Hand (DASH) score
timeFrame: 3 months after explantation
Secondary outcomes:
measure: Visual analogue scale (VAS) pain
timeFrame: 3 months after explantation
measure: Functional assessment: Goniometry
timeFrame: 3 months after explantation
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Waldfriede Hospital
Study officials:
affiliation: Waldfriede Hospital
name: Markus Bock, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Waldfriede Hospital
name: Martin Lautenbach, MD
role: STUDY_CHAIR
References:
Clinical trial NCT05470049: A Clinical Study of the Combination of SHR8554 Injection and SHR0410 Injection for the Treatment of Pain After Abdominal Surgery.
Official title: A Phase II, Randomized, Double-Blind Study of the Combination of SHR8554 Injection and SHR0410 Injection for the Treatment of Pain After Abdominal Surgery.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Pain
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2022-07-22
Enrollment: 108
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel Assignment
Primary purpose: TREATMENT

Brief summary: The primary objective is to evaluate the analgesic efficacy of the combination of SHR8554 injection and SHR0410 injection compared with SHR8554 injection in patients with acute postoperative pain following abdominal surgery


Eligibility criteria: Inclusion Criteria:

1. Able and willing to provide a written informed consent
2. Subjects requiring elective general anesthesia abdominal surgery
3. Conform to the ASA Physical Status Classification

Exclusion Criteria:

1. Subjects with a history of difficult airway
2. Subjects with a history of reflux esophagitis
3. Subjects with a history of mental illness
4. Subjects with poor blood pressure control
5. Random blood glucose ≥11.1mmol/L
6. Subjects with abnormal liver function
7. allergies to opioids and other medications that may be used during the trial
8. The investigators determined that other conditions were inappropriate for participation in this clinical trial

Primary outcomes:
measure: the Sum of Pain Intensity Differences in Pain Score Over 24 Hours
timeFrame: 24-hours
Secondary outcomes:
measure: the Sum of Pain Intensity Differences in Pain Score Over 6、12、12-24 Hours
timeFrame: 6-hours、12-hours、12-24 hours
measure: Time of first use of remedial analgesic medication
timeFrame: 24-hours
measure: Cumulative use of remedial analgesics from 0h to 24h
timeFrame: 24-hours
measure: Participant ' satisfaction score for analgesia treatment
timeFrame: 24-hours
measure: Investigator satisfaction score for analgesia treatment
timeFrame: 24-hours
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00090649: Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study Of DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Major Depressive Disorder
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2004-09-01
Enrollment: 369
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the antidepressant efficacy and safety of DVS-233 SR with those of placebo in adult outpatients with MDD.


Eligibility criteria: Inclusion Criteria:

* Men and women 18 to 75 years of age, inclusive.
* Sexually active individuals participating in the study must use a medically acceptable form of contraception during the study and for at least 15 days after the last dose of test article
* Subjects must have a primary diagnosis of major depressive disorder

Exclusion Criteria:

* Treatment with DVS-233 SR at any time in the past
* Treatment with venlafaxine (immediate release \[IR\] or extended release \[ER\]) within 90 days of study day 1
* Known hypersensitivity to venlafaxine (IR or ER)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor, MD
role: STUDY_DIRECTOR
References: